Marken announced that it has significantly upgraded its existing operating system with a centralized web-based software exclusively designed for its growing supply chain organization. The system, known as ‘Maestro’ has a flexible architecture which will enable extensive tracking of shipments, integrated documentation, client reporting, and performance monitoring. It is designed explicitly for ease of integration with client’s systems to meet their growing requirements with temperature and time sensitive drugs to be shipped worldwide. Its interfaces and flexible structure enables each of its clients to input and track relevant data connected with a clinical trial and manage the hand-offs between shipments from site to lab and country to country. This new operating system, when coupled with Marken’s new Solo™ system for its depot operations, will allow Marken to manage the complete inbound and outbound cycle for clinical trials.
“We are very proud to announce the new Maestro system to our clients”, said Cyril Leger, Chief Operating Officer, Marken LLC. “We have been working on this new system for many months and have incorporated our best thinking as well as feedback from our clients. Our customer service representatives can now work more efficiently around the clock, across all of our 24 branch locations, and track shipments more precisely than ever before”.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.